Home : Unsafe Drugs : Procrit : News Articles

Procrit - News Articles

Participating In A Clinical Trial – Part 1: What Are My Options And How Do I Go About Finding Or Choosing One? - The MDS Beacon


For example, a large study that opened in late 2008 was designed to compare Procrit (epoetin) treatment to placebo in patients with MDS. The FDA required Johnson & Johnson, the company that sells Procrit, to conduct the study because of safety concerns that have emerged since 2005 with erythropoietin (Procrit and Aranesp (darbepoetin)) use in patients with certain types of tumors ...
Deadly performance enhancer - Thoroughbred Times


Epogen, also marketed as Procrit, was developed by the research company Amgen Inc. to aid humans with severe anemia caused by acute kidney failure or cancer treatment. Anemia is a decrease in red blood cells, which carry oxygen from the lungs to the rest of the body. When red blood cells become depleted, extreme fatigue results because the body cannot function without ...
Veterinary Spotlight: Abuse with unknown perils - Thoroughbred Times


Epoetin alfa is considered a life-saving drug for humans with severe anemia and is better known by the trademarks Epogen and Procrit. Natural erythropoietin is a protein produced by the kidneys that circulates through the bloodstream to the bone marrow and into the cells that are being produced, and then shoves it in there to make hemoglobin. Then, those ...
Mesothelioma Blog | Anemia Drugs May Decrease Survival Time Among Cancer Patients


As a result, ESAs such as Procrit, Epogen and Arenesp are frequently prescribed to stimulate the production of additional red blood cells. While such medications are typically preferred over the alternative of blood transfusions, experts warn that such drugs have been linked to reduced survival times of cancer patients. An increased risk of internal blood clotting has ...
Spectrum Pharmaceuticals Appoints Steven M. Fruchtman, MD, an Industry Veteran, as Vice President of Clinical Development


(Multiple Myeloma and NHL), Velcade and DOXIL ® for 2 nd line Multiple Myeloma, Zarnestra ® (tipifarnib) Phase 1 and 2 trials in MDS and AML, Procrit ® for MDS, and Yondelis ® (trabectedin) Trials in Soft Tissue Sarcoma and Ovarian Cancer. Dr. Fruchtman has served as an external reviewer for the New England Journal of Medicine, Mayo Clinic Proceedings, Experimental ...
FDA Declines J&J's Bid For Less Frequent Dosing Of Procrit - WSJ.com


The US Food and Drug Administration declined to approve Johnson & Johnson's (JNJ) application to market a less frequent dosing schedule for its anti-anemia drug Procrit. J&J received a so-called "complete ...
US FDA advisory panel backs continued use of Amgen’s Aranesp and Epogen pre-dialysis, but calls for more studies - Pharmaceutical and Biotechnology News - Pharma Letter


alfa) and Johnson & Johnson's (NYSE: JNJ) Procrit (epoetin alfa) should remain on the market for anemia patients who do not yet require dialysis, despite an increased risk of stroke as identified in the TREAT clinical study. Amgen’s stock rise 2.2% to $57.96 ...
Glass Flakes Found in Anemia Drugs | InjuryBoard New York City


On September 24, 2010, Amgen announced that certain lots of anemia drugs Epogen and Procrit vials are being voluntarily recalled because they may contain glass flakes. These drugs are used to treat anemia related to HIV therapy, chronic renal failure, and chemotherapy. The ...
Redirect Notice

FiercePharma
The medicines — Procrit, Aranesp and Epogen — are multibillion dollar sellers because of their ability to boost oxygen-carrying red blood cells, ...
Advisory Panel Backs Anemia Drugs For Kidney Failure Patients : dBTechno

BusinessWeek
The main anemia drugs at play here are Procrit, Aranesp and Epogen. The panel voted 15-1 in favor of allowing these drugs to be given to kidney failure patients, but the FDA will have the final word and do not have to side with their advisory panels. ...
Octogenarian does dialysis at home | brownsville, dialysis, home - Valley and State - Brownsville Herald


Because many dialysis patients can become anemic, they must receive regular injections of a drug such as Epogen or Procrit. “They get this injection ...
Judge’s decision has broad implications for generic versions of biologic drugs and companies who make them - BioMedReports.com


in particular, Teva's (NASDAQ:TEVA) $2.8 billion blockbuster Copaxone and Amgen's Procrit/Epogen and Enbrel which had US sales of over $6.5 billion. These will certainly be main targets in the follow-on biologics war that is coming and other big pharmas have ...
US Nephrologists Report Management Changes in Kidney Disease - MarketWatch


Currently only 39 percent and 50 percent of Nephrologists respectively, report that Amgen's Aranesp and Centocor Ortho-Biotech's Procrit perform well on long-term safety and the mean safety ratings for both of these products have decreased significantly compared to the prior ...
Cera – medaljens bakside | www.siste.no


En rekke varianter fins av legemiddelet EPO; Procrit, Eprex, Neorecormon, Aranesp, Dynepo, PDpoetin og Mircera er noen. Naturlig EPO er et hormon som produseres i nyrene, virker i beinmargen og øker produksjonen av hemoglobin i de røde blodcellene. Dermed vil utholdenheten bedres ...
RCM Pharma - Marketing Farmacêutico - Actualidade


No lado oposto encontram-se classes cujo mercado está a diminuir: as eritropoietinas (como o Anaresp®, Epogen® e Procrit®) registaram um forte crescimento até 2007, mas as vendas destes produtos caíram cerca de 20% um ano depois das advertências de segurança de ...
:: Clinical Oncology News ::


In April 2008, the FDA required Amgen Inc., to establish and oversee a REMS program for ESAs, which include epoetin alfa (Procrit, Centocor Ortho Biotech; ...
Clinical Trial Results Affect Several Stocks - IBD - Investors.com


Amgen also makes Procrit, sold by Johnson & Johnson (JNJ). "Hematide would be beneficial because it would be one step toward finding a lower-cost ...
Medicare mulls new restrictions on anemia meds - FiercePharma


Various studies and analyses have suggested that the class of drugs--including Epogen and Aranesp from Amgen and J&J's Procrit--can cause tumor growth in ...
Dendreon's Medicare Coverage Conundrum - TheStreet


One additional and commonly cited NCD in the cancer arena is for the red blood cell stimulating drugs Epogen, Aranesp and Procrit. ...
J&J on Hook for "Hundreds of Millions" Over Technicality in Anemia Drug Case | BNET Pharma Blog | BNET


The suit alleges that 80 percent of Procrit's sales are fraudulent; the drug makes $2.2 billion a year for the company. It also names dozens of doctors who ...
Want to contact a Washington, DC Procrit attorney? ...Get a free case evaluation from one of our Washington, DC Procrit attorneys now.
Pages:   1   2   3   Next

Need A Procrit Attorney?

First Name Last Name Email Address State
Was Your Health Negatively Affected?

Please Describe the Injury

Your Friend's Email Address

Your Email Address

Type a Message (optional)


Want to contact a Washington, DC Procrit attorney? ...Get a free case evaluation from one of our Washington, DC Procrit attorneys now.

 

Close (x)

Looking for an Attorney?


Please type your question:

Close (x)

logo Find Legal Help for Your Procrit Case - Submit Your Information Below

Do you need legal assistance with your Procrit case?
LegalView may be able to help.


Submit your information below for a free, no-cost evaluation.

We'll submit your information to one of our partner firms.
LegalView's partners represent clients throughout the United States, for a very wide range of legal issues. Submit your information now, to see if one of LegalView's partners can help!

* Indicates Required Fields

First name *
Last name *
Email Address *
Phone Number *
()  -

State *
Legal Issue * Unsafe Drugs: Procrit Change
Was There an Injury?
Please Describe The Injury

DISCLAIMER and STATEMENT OF NON-CONFIDENTIALITY

By submitting this form, you agree that completing the above is not intended to create an attorney-client relationship.

Disclosure

Legal WebTV Network LLC, LegalView.com, and LegalWebMedia.com are group advertising sponsored by the attorneys identified here. It is not a lawyer referral service. If you submit information on this website [more...]

Legal WebTV Network LLC, LegalView.com, and LegalWebMedia.com are group advertising sponsored by the attorneys identified here. It is not a lawyer referral service. If you submit information on this website, LegalWebMedia.com will submit your information to the law firms that pay for this group advertising and to respond to your requests for information concerning legal services in their assigned local areas. If there is no sponsoring firm in your state, your inquiry will be submitted to one of the sponsoring law firms on a predetermined, rotating basis. If the sponsoring law firm accepts your case, it will associate with licensed attorneys practicing in your state, if required; the sponsoring law firm may also contact other law firms to see if they may be able to assist.

The information provided by the LegalView.com and LegalWebMedia.com websites is for advertising and informational purposes and should not be considered as legal advice from the sponsoring attorneys. The websites contain general information and may not reflect current legal developments, verdicts, or settlements. LegalView.com contains information created by others or supplied through open forums; the sponsoring law firms are not responsible for the accuracy of this information. Any person viewing or receiving information from these websites should not act or refrain from acting on the basis of any such information without first seeking appropriate legal advice from an attorney in your area. Legal WebTV Network, LLC expressly disclaims any liability with respect to actions taken or not taken by the recipient based on any or all of the information or contents contained in these websites.

Any information sent to Legal WebTV Network LLC through this website is done using standard Web encryption techology. LegalView.com will exercise all reasonable care, within technological limits, to protect the confidentiality of any information submitted via Internet e-mail or through this website. By accessing this website, you may be seeking an attorney to represent you or legal advice. However, none of the sponsoring attorneys represent you yet.

The choice of a lawyer is an important decision and should not be based solely upon advertisements.

Any transmission of information, whether via Internet e-mail or through the website, is solely for evaluation purposes by the sponsoring law firms and their associates. The transmission of any information to any attorney sponsoring advertising on LegalView.com or LegalWebMedia.com does not create an attorney-client relationship between the sender and any recipient. An attorney-client relationship can only be created by a written, signed-fee agreement entered into with an attorney. The sponsoring attorneys will treat your information as a confidential communication for the purpose of obtaining legal services or legal advice.

For more information about the sponsoring law firms, please click here.
This form is secure and encrypted. More information about secure forms and your privacy here.